Asia
The parent company of JSR Life Sciences snapped up CRO Crown Bioscience International for $400M, the company announced this morning.
Should you invest the way billionaire investors do?
The Israeli government isn’t considering punitive measures against debt-strapped Teva over its plan to fire a quarter of its Israeli work force, according to an official close to Prime Minister Benjamin Netanyahu.
Chiome Bioscience says it announces termination of candidate antibody related joint research contract, which was signed between the co and Chugai Pharma, as the contract has expired on Dec. 31
Clover Biopharmaceuticals, a Chengdu biotech startup, completed a $9.5M Series A financing led by Tianhe Life Sciences Venture Fund.
Teva pulled the trigger on a comprehensive restructuring plan that includes the elimination of 25 percent of the company’s global workforce.
Kangmei will supply the JV with 95% of the $7.6M in cash, while BGI will contribute the remaining 5% of the JV’s value with instruments and technology.
The French executive made the public apology after he was castigated by SAGIP Rep. Rodante Marcoleta for his company’s “insensitivity” to the concerns of the Filipino public.
Daiichi Sankyo informed Nektar that it was terminating a collaboration and licensing deal, effective Feb. 4, 2018.
It seems those thousands of anticipated and dreaded pink slips at Teva will be handed out on Thursday.
PRESS RELEASES